Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% ...

The high list prices of these new weight loss drugs are costly for ... have been in short supply since 2022, but the FDA declared on Oct. 2 the drugs were no longer in shortage.

They've been dubbed 'game-changers' in the world of obesity, making the seemingly impossible, possible - significant weight ...

Ozempic — or any of the GLP-1 class of diet drugs that includes Wegovy and Mounjaro — hasn’t just changed our nation’s ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...

New studies in JACC highlight improvements in cardiac structure and function among CABG patients, as well as changes in ...